Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04129151 · ClinicalTrials.gov registry record · Phase 2
Palbociclib + Ganitumab In Ewing Sarcoma
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT04129151 is a Phase 2 study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 10 participants.
The verdict
NCT04129151, a Phase 2 study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This research study is designed to study the combination of two drugs, palbociclib and ganitumab, as a potential treatment for Ewing sarcoma. The names of the study drugs involved in this study are: * Palbociclib * Ganitumab
Interventions
- DRUG Palbociclib
- DRUG Ganitumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-12-05 |
| Est. Completion | 2022-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04129151
The ClinicalTrials.gov registry entry for NCT04129151 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Palbociclib is the first listed.
NCT04129151 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04129151 about?
NCT04129151 is a clinical study titled "Palbociclib + Ganitumab In Ewing Sarcoma". This research study is designed to study the combination of two drugs, palbociclib and ganitumab, as a potential treatment for Ewing sarcoma. The names of the study drugs involved in this study are: * Palbociclib * Ganitumab
What is the current status of trial NCT04129151?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2019-12-05. Estimated completion is 2022-12-15.
What interventions are being tested in trial NCT04129151?
The interventions under investigation include: Palbociclib (DRUG), Ganitumab (DRUG).
Who is sponsoring clinical trial NCT04129151?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.